|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Revance Therapeutics, Inc.
| | | Phone: | (510) 742-3400 | Fax: | (510) 742-3401 | Year Established: | 2002 | Ticker: | RVNC | Exchange: | NASDAQ | Main Contact: | Todd Zavodnick, CCO | | Other Contacts: | Susanne Fors, VP, Regulatory Affairs Caryn McDowell, Senior VP & General Counsel Abhay Joshi, Ph.D., COO Erica Bazerkanian, Senior Director, Strategic Marketing Azita Nejad, VP, Quality and Validations Samir Gharib, VP, Finance and Administration Mukul Agarwal, VP, Business Development Roman G. Rubio, M.D., Senior VP, Clinical Development Dan Browne, Co-Founder, President & CEO Tobin C. Schilke, CFO
| | Company Description | Revance is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology, orthopedics and neurology. Revance's science is based upon a proprietary peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing DaxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. | |
|
|
|
|
|